LIFE - aTyr Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.2000

-0.0600

(-2.65%)

At close: 04:00PM EDT

2.2000

0.00

(0.00%)

After hours:

06:12PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Outside Bar (Bearish)

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	2.2600
Open	2.2700
Bid	2.2000 x 2900
Ask	2.2400 x 1400
Day's Range	2.1900 - 2.2700
52 Week Range	1.5550 - 4.2800
Volume	285,017
Avg. Volume	653,166

Market Cap	127.586M
Beta (5Y Monthly)	1.22
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LIFE

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

News

Investing.com
Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data
Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: Sana Biotech, aTyr Pharma, and Theseus Pharma are set to share new data, and the FDA is set to review a Lexicon Pharma compound.
Simply Wall St.
aTyr Pharma Independent Director Acquires 25% More Stock \
Potential aTyr Pharma, Inc. ( NASDAQ:LIFE ) shareholders may wish to note that the Independent Director, Paul Schimmel...
Simply Wall St.
aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
Zacks
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
InvestorPlace
3 Stocks and Cryptos With the Highest Potential Returns
If you are only concerned about upside potential, looking into some stocks and cryptos with high returns is the way to go. The current environment is indeed very risky, with a recent rate hike and a recession on the horizon. Still, there are high-risk, high-return assets that can deliver multibagger gains if you’re lucky. However, I would note that chasing high upside potential comes with a lot of risks as you’d have to step foot into speculative territory. But the rewards can be just as rewardi
InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear. Those same investors should also be well aware that they’ll be investing in cheaper stocks generally. Lower-priced shares have greater potential to multiply in value. That means investors looking for three-baggers will be looking at penny stocks which are, again, risky. Okay, you get it, to triple one’s capital in less than a year requires significant risk. However,
TipRanks
2 “Strong Buy” Penny Stocks With Over 200% Upside on the Horizon
Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds. However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in t
Simply Wall St.
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Zacks
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Simply Wall St.
With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest
To get a sense of who is truly in control of aTyr Pharma, Inc. ( NASDAQ:LIFE ), it is important to understand the...
Insider Monkey
aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript
aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript November 10, 2022 aTyr Pharma, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Good afternoon, ladies and gentlemen and welcome to aTyr Pharma’s Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. Later, […]
Zacks
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Simply Wall St.
Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year
Quite a few insiders have dramatically grown their holdings in aTyr Pharma, Inc. ( NASDAQ:LIFE ) over the past 12...